Neurobiology of Alzheimer's Disease

Basic Neurochemistry

Volumn , Issue , 2012, Pages 815-828

  Wong, Philip C ^a   Savonenko, Alena ^a   Li, Tong ^a   Price, Donald L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882530203     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374947-5.00046-8     Document Type: Chapter

References (123)

1. Ahn K., Shelton C.C., Tian Y., Zhang X., Gilchrist M.L., Sisodia S.S., et al. Activation and intrinsic {gamma}-secretase activity of presenilin 1. Proceedings of the National Academy of Sciences of the United States of America 2010.
2. Ashe K.H., et al. Probing the biology of Alzheimer's disease in mice. Neuron 2010, 66:631-645.
3. Bacskai B.J., Hickey G.A., Skoch J., Kajdasz S.T., Wang Y., Huang G.F., et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:12462-12467.
4. Ballatore C., Lee V.M.Y., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews Neuroscience 2007, 8:663-672.
5. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Medicine 2000, 6:916-919.
6. Bateman R.J., Munsell L.Y., Morris J.C., Swarm R., Yarasheski K.E., Holtzman D.M. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nature Medicine 2006, 12:856-861.
7. Bateman R.J., Siemers E.R., Mawuenyega K.G., Wen G., Browning K.R., Sigurdson W.C., et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Annals of Neurology 2009, 66:48-54.
8. Bertram L., Tanzi R.E. Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses. Nature Reviews. Neuroscience 2008, 9:768-778.
9. Bishop N.A., Lu T., Yankner B.A. Neural mechanisms of ageing and cognitive decline. Nature 2010, 464:529-535.
10. Borchelt D.R., Ratovitski T., Van Lare J., Lee M.K., Gonzales V., Jenkins N.A., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
11. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitski T., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013.
12. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica 1991, 82:239-259.
13. Brody D.L., Holtzman D.M. Active and passive immunotherapy for neurodegenerative disorders. Annual Review of Neuroscience 2008, 31:175-193.
14. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health 1998, 88:1337-1342.
15. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: Pathways, pathogenesis and therapy 1. Nature Reviews. Neuroscience 2009, 10:333-344.
16. Buckner R.L., Andrews-Hanna J.R., Schacter D.L. The brain's default network: Anatomy, function, and relevance to disease 1. Annals of the New York Academy of Sciences 2008, 1124:1-38.
17. Buxbaum J.D., Thinakaran G., Koliatsos V., O'Callahan J., Slunt H.H., Price D.L., et al. Alzheimer amyloid protein precursor in the rat hippocampus: Transport and processing through the perforant path. The Journal of Neuroscience 1998, 18:9629-9637.
18. Cai H., Wang Y., McCarthy D., Wen H., Borchelt D.R., Price D.L., et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nature Neuroscience 2001, 4:233-234.
19. Cao X., Sudhof T.C. A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001, 293:115-120.
20. Capell A., Steiner H., Romig H., Keck S., Baader M., Grim M.G., et al. Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch. Nature Cell Biology 2000, 2:205-211.
21. Caughey B., Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annual Review of Neuroscience 2003, 26:267-298.
22. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neuroscience 1999, 2:271-276.
23. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., et al. A learning deficit related to age and b-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000, 408:975-979.
24. Chow, V., Savonenko, A., Melnikova, T., Kim, H., Price, D., Li, T., et al. (2010a). Modeling an anti-amyloid combination therapy for Alzheimer's disease. Ref Type: Serial (Book, Monograph).
25. Chow V.W., Savonenko A.V., Melnikova T., Kim H., Price D.L., Li T., et al. Modeling an anti-amyloid combination therapy for Alzheimer's disease. Science Translational Medicine 2010, 2:13ra1.
26. Cirrito J.R., May P.C., O'Dell M.A., Taylor J.W., Parsadanian M., Cramer J.W., et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. The Journal of Neuroscience 2003, 23:8844-8853.
27. Citron M. Alzheimer's disease: Strategies for disease modification. Nature Reviews. Drug Discovery 2010, 9:387-398.
28. de Calignon A., Fox L.M., Pitstick R., Carlson G.A., Bacskai B.J., Spires-Jones T.L., et al. Caspase activation precedes and leads to tangles. Nature 2010, 464:1201-1204.
29. De Strooper B. Aph-1, Pen-2, and Nicastrin with presenilin generate an active gamma-secretase complex. Neuron 2003, 38:9-12.
30. De Strooper B., Annaert W.G., Cupers P., Saftig P., Craessaerts K., Mumm J.S., et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999, 398:518-522.
31. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295:2264-2267.
32. Doan A., Thinakaran G., Borchelt D.R., Slunt H.H., Ratovitski T., Podlisny M., et al. Protein topology of presenilin 1. Neuron 1996, 17:1023-1030.
33. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nature Neuroscience 2002.
34. Edbauer D., Winkler E., Haass C., Steiner H. Presenilin and nicastrin regulate each other and determine amyloid beta- peptide production via complex formation. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:8666-8671.
35. Esler W.P., Kimberly W.T., Ostaszewski B.L., Diehl T.S., Moore C.L., Tsai J.Y., et al. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nature Cell Biology 2000, 2:428-434.
36. Esler W.P., Kimberly W.T., Ostaszewski B.L., Ye W., Diehl T.S., Selkoe D.J., et al. Activity-dependent isolation of the presenilin-y-secretase complex reveals nicastrin and a y substrate. Proceedings of the National Academy of Sciences 2002, 14:1-6.
37. Farzan M., Schnitzler C.E., Vasilieva N., Leung D., Choe H. BACE2, a b-secretase homolog, cleaves at the b site and within the amyloid-b region of the amyloid-b precursor protein. Proceedings of the National Academy of Sciences 2000, 97:9712-9717.
38. Frisardi V., Solfrizzi V., Imbimbo P.B., Capurso C., D'Introno A., Colacicco A.M., et al. Towards disease-modifying treatment of Alzheimer's disease: Drugs targeting beta-amyloid. Current Alzheimer Research 2010, 7:40-55.
39. Gamblin T.C., Chen F., Zambrano A., Abraha A., Lagalwar S., Guillozet A.L., et al. Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:10032-10037.
40. Ghaemmaghami S., Ullman J., Ahn M., Martin S., Prusiner S.B. Chemical induction of misfolded prion protein conformers in cell culture. The Journal of Biological Chemistry 2010, 285:10415-10423.
41. Goedert M., Spillantini M.-G. Neurodegenerative alpha-Synucleinopathies and tauopathies. Basic neurochemistry: Molecular, cellular, and medical aspects 2006, 745-759. Elsevier. 7th ed. Siegel, Albers, Brady, Price (Eds.).
42. Golde T.E., Schneider L.S., Koo E.H. Anti-abeta therapeutics in Alzheimer's disease: The need for a paradigm shift. Neuron 2011, 69:203-213.
43. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., et al. Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:10417-10422.
44. Gotz J., Chen F., Van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta fibrils. Science 2001, 293:1491-1495.
45. Gotz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nature Reviews. Neuroscience 2008, 9:532-544.
46. Goutte C., Tsunozaki M., Hale V.A., Priess J.R. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:775-779.
47. Haass C. Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. The EMBO Journal 2004, 23:483-488.
48. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics 2009, 41:1088-1093.
49. Heber S., Herms J., Gajic V., Hainfellner J., Aguzzi A., Rulicke T., et al. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. The Journal of Neuroscience 2000, 20:7951-7963.
50. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proceedings of the National Academy of Sciences 1999, 96:3228-3233.
51. Iwatsubo T. The gamma-secretase complex: Machinery for intramembrane proteolysis. Current Opinion in Neurobiology 2004, 14:379-383.
52. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
53. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Human Molecular Genetics 2004, 13:159-170.
54. Jankowsky J.L., Slunt H.H., Gonzales V., Savonenko A.V., Wen J.C., Jenkins N.A., et al. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Medicine 2005, 2:e355.
55. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., et al. APP processing and synaptic function. Neuron 2003, 37:925-937.
56. Khlistunova I., Biernat J., Wang Y.P., Pickhardt M., von Bergen M., Gazova Z., et al. Inducible expression of tau repeat domain in cell models of tauopathy-aggregation is toxic to cells but can be reversed by inhibitor drugs. Journal of Biological Chemistry 2006, 281:1205-1214.
57. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
58. Kim J., Castellano J.M., Jiang H., Basak J.M., Parsadanian M., Pham V., et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 2009, 64:632-644.
59. Kistner A., Gossen M., Zimmermann F., Jerecic J., Ullmer C., Lubbert H., et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:10933-10938.
60. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomstrand G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease using the novel positron emission tomography tracer, Pittsburgh Compund-B. Annals of Neurology 2004, 55:1-14.
61. Koo E.H., Kopan R. Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nature Medicine 2004, 10(Suppl.):S26-S33.
62. Koo E.H., Sisodia S.S., Archer D.R., Martin L.J., Weidemann A., Beyreuther K.T., et al. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proceedings of the National Academy of Sciences 1990, 87:1561-1565.
63. Kotilinek L.A., Bacskai B.J., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. The Journal of Neuroscience 2002, 22:6331-6335.
64. Kounnas M.Z., Danks A.M., Cheng S., Tyree C., Ackerman E., Zhang X., et al. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010, 67:769-780.
65. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annual Review of Neuroscience 2001, 24:1121-1159.
66. Lewis J., Dickson D.W., Lin W.-L., Chisholm L., Corral A., Jones G., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutat tau and APP. Science 2001, 293:1487-1491.
67. Li R., Lindholm K., Yang L.B., Yue X., Citron M., Yan R., et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:3632-3637.
68. Li T., Ma G., Cai H., Price D.L., Wong P.C. Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals. The Journal of Neuroscience 2003, 23:3272-3277.
69. Li Y.M., Xu M., Lai M.T., Huang Q., Castro J.L., DiMuzio-Mower J., et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000, 405:689-694.
70. Liu Y., Yoo M.J., Savonenko A., Stirling W., Price D.L., Borchelt D.R., et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. The Journal of Neuroscience 2008, 28:13805-13814.
71. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. The American Journal of Pathology 1999, 155:853-862.
72. Luo Y., Bolon B., Kahn S., Bennett B.D., Babu-Khan S., Denis P., et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nature Neuroscience 2001, 4:231-232.
73. Ma G., Li T., Price D.L., Wong P.C. APH-1a is the principal mammalian APH-1 isoform present in gamma-secretase complexes during embryonic development. The Journal of Neuroscience 2005, 25:192-198.
74. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. The Journal of Neuroscience 2007, 27:10957-10968.
75. Marjaux E., Hartmann D., De Strooper B. Presenilins in memory, Alzheimer's disease, and therapy. Neuron 2004, 42:189-192.
76. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
77. Monsonego A., Weiner H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 2003, 302:834-838.
78. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. Ab peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
79. Morris J.C., Price J.L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. Journal of Molecular Neuroscience 2001, 17:101-118.
80. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., et al. Mild cognitive impairment represents early-stage Alzheimer disease. Archives of Neurology 2001, 58:397-405.
81. Naruse S., Thinakaran G., Luo J.J., Kusiak J.W., Tomita T., Iwatsubo T., et al. Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron 1998, 21:1213-1221.
82. Nestor P.J., Scheltens P., Hodges J.R. Advances in the early detection of Alzheimer's disease. Nature Medicine 2004, 10(Suppl.):S34-S41.
83. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
84. Ohno M., Sametsky E.A., Younkin L.H., Oakley H., Younkin S.G., Citron M., et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 2004, 41:27-33.
85. Perrin R.J., Fagan A.M., Holtzman D.M. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009, 461:916-922.
86. Petersen R.C. Mild cognitive impairment clinical trials. Nature Reviews. Drug Discovery 2003, 2:646-653.
87. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., et al. Current concepts in mild cognitive impairment. Archives of Neurology 2001, 58:1985-1992.
88. Price D.L., Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annual Review of Neuroscience 1998, 21:479-505.
89. Price D.L., Tanzi R.E., Borchelt D.R., Sisodia S.S. Alzheimer's disease: Genetic studies and transgenic models. Annual Review of Genetics 1998, 32:461-493.
90. Querfurth H.W., LaFerla F.M. Alzheimer's disease. The New England Journal of Medicine 2010, 362:329-344.
91. Reddy M.M., Wilson R., Wilson J., Connell S., Gocke A., Hynan L., et al. Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 2011, 144:132-142.
92. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nature Genetics 2007, 39:168-177.
93. Sagare A., Deane R., Bell R.D., Johnson B., Hamm K., et al. Clearance of amyloid by circulating lipoprotein receptors. Nature Medicine 2011, 1029-1031.
94. Savonenko A.V., Melnikova T., Laird F.M., Stewart K.A., Price D.L., Wong P.C. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:5585-5590.
95. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
96. Selkoe D., Kopan R. Notch and presenilin: Regulated intramembrane proteolysis links development and degeneration. Annual Review of Neuroscience 2003, 26:565-597.
97. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
98. Shen J., Bronson R.T., Chen D.F., Xia W., Selkoe D.J., Tonegawa S. Skeletal and CNS defects in presenilin-1-deficient mice. Cell 1997, 89:629-639.
99. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375:754-760.
100. Sisodia S.S., George-Hyslop P.H. gamma-Secretase, Notch, Abeta and Alzheimer's disease: Where do the presenilins fit in?. Nature Reviews. Neuroscience 2002, 3:281-290.
101. Sisodia S.S., Koo E.H., Beyreuther K.T., Unterbeck A., Price D.L. Evidence that b-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 1990, 248:492-495.
102. Sisodia S.S., Koo E.H., Hoffman P.N., Perry G., Price D.L. Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. The Journal of Neuroscience 1993, 13:3136-3142.
103. Sperling R.A., Laviolette P.S., O'Keefe K., O'Brien J., Rentz D.M., Pihlajamaki M., et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009, 63:178-188.
104. Steiner H., Winkler E., Edbauer D., Prokop S., Basset G., Yamasaki A., et al. PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin. The Journal of Biological Chemistry 2002, 277:39062-39065.
105. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proceedings of the National Academy of Sciences 1997, 94:13287-13292.
106. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA: The Journal of the American Medical Association 2003, 289:2094-2103.
107. Takasugi N., Tomita T., Hayashi I., Tsuruoka M., Niimura M., Takahashi Y., et al. The role of presenilin cofactors in the gamma-secretase complex. Nature 2003, 422:438-441.
108. Thinakaran G., Harris C.L., Ratovitski T., Davenport F., Slunt H.H., Price D.L., et al. Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. The Journal of Biological Chemistry 1997, 272:28415-28422.
109. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., et al. b-secretase cleavage of Alzheimer's amyloid precusor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
110. Vassar R., Kovacs D.M., Yan R., Wong P.C. The beta-secretase enzyme BACE in health and Alzheimer's disease: Regulation, cell biology, function, and therapeutic potential. The Journal of Neuroscience 2009, 29:12787-12794.
111. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
112. Wang Y., Garg S., Mandelkow E.M., Mandelkow E. Proteolytic processing of tau. Biochemical Society Transactions 2010, 38:955-961.
113. Wang Y.P., Biernat J., Pickhardt M., Mandelkow E., Mandelkow E.M. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:10252-10257.
114. Wengenack T.M., Reyes D.A., Curran G.L., Borowski B.J., Lin J., Preboske G.M., et al. Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. Neuroimage 2011, 54:113-122.
115. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Annals of Neurology 1981, 10:122-126.
116. Wolfe M.S. Therapeutic strategies for Alzheimer's disease. Nature Reviews. Drug Discovery 2002, 1:859-866.
117. Wong P.C., Cai H., Borchelt D.R., Price D.L. Genetically engineered mouse models of neurodegenerative diseases. Nature Neuroscience 2002, 5:633-639.
118. Wong P.C., Price D.L., Cai H. The brain's susceptibility to amyloid plaques. Science 2001, 293:1434-1435.
119. Wong P.C., Zheng H., Chen H., Becher M.W., Sirinathsinghji D.J., Trumbauer M.E., et al. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature 1997, 387:288-292.
120. Xia P., Chen H.S., Zhang D., Lipton S.A. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. The Journal of Neuroscience 2010, 30:11246-11250.
121. Yan R., Bienkowski M.J., Shuck M.E., Miao H., Tory M.C., Pauley A.M., et al. Membrane-anchored aspartyl protease with Alzheimer's disease b-secretase activity. Nature 1999, 402:533-537.
122. Yang L.B., Lindholm K., Yan R., Citron M., Xia W., Yang X.L., et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nature Medicine 2003, 9:3-4.
123. Zhang D., Raichle M.E. Disease and the brain's dark energy. Nature Reviews Neurology 2010, 6:15-28.